|
1
|
Weng L, Wu X, Gao H, Mu B, Li X, Wang JH,
Guo C, Jin JM, Chen Z, Covarrubias M, et al: MicroRNA profiling of
clear cell renal cell carcinoma by whole-genome small RNA deep
sequencing of paired frozen and formalin-fixed, paraffin-embedded
tissue specimens. J Pathol. 222:41–51. 2010.PubMed/NCBI
|
|
2
|
Devita VT Jr, Hellman S and Rosenberg SA:
Cancer principles and practice of oncology. 8th edition. Lippincott
Williams & Wilkins; Philadelphia, PA: 2008
|
|
3
|
Fridman E, Dotan Z, Barshack I, David MB,
Dov A, Tabak S, Zion O, Benjamin S, Benjamin H, Kuker H, et al:
Accurate molecular classification of renal tumors using microRNA
expression. J Mol Diagn. 12:687–696. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Aben KK, Luth TK, Janssen-Heijnen ML,
Mulders PF, Kiemeney LA and van Spronsen DJ: No improvement in
renal cell carcinoma survival: A population-based study in the
Netherlands. Eur J Cancer. 44:1701–1709. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Capitanio U, Cloutier V, Zini L, Isbarn H,
Jeldres C, Shariat SF, Perrotte P, Antebi E, Patard JJ, Montorsi F
and Karakiewicz PI: A critical assessment of the prognostic value
of clear cell, papillary and chromophobe histological subtypes in
renal cell carcinoma: A population-based study. BJU Int.
103:1496–1500. 2009. View Article : Google Scholar
|
|
6
|
Slaby O, Jancovicova J, Lakomy R, Svoboda
M, Poprach A, Fabian P, Kren L, Michalek J and Vyzula R: Expression
of miRNA-106b in conventional renal cell carcinoma is a potential
marker for prediction of early metastasis after nephrectomy. J Exp
Clin Cancer Res. 29:902010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hidaka H, Seki N, Yoshino H, Yamasaki T,
Yamada Y, Nohata N, Fuse M, Nakagawa M and Enokida H: Tumor
suppressive microRNA-1285 regulates novel molecular targets:
Aberrant expression and functional significance in renal cell
carcinoma. Oncotarget. 3:44–57. 2012.PubMed/NCBI
|
|
9
|
Vermes I, Haanen C, Steffens-Nakken H and
Reutelingsperger C: A novel assay for apoptosis. Flow cytometric
detection of phosphatidylserine expression on early apoptotic cells
using fluorescein labelled Annexin V. J Immunol Methods. 184:39–51.
PubMed/NCBI
|
|
10
|
Annaratone L, Volante M, Asioli S, Rangel
N and Bussolati G: Characterization of neuroendocrine tumors of the
pancreas by real-time quantitative polymerase chain reaction. A
methodological approach. Endocr Pathol. 24:83–91. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tie J, Pan Y, Zhao L, Wu K, Liu J, Sun S,
Guo X, Wang B, Gang Y, Zhang Y, et al: MiR-218 inhibits invasion
and metastasis of gastric cancer by targeting the Robo1 receptor.
PLoS Genet. 6:e10008792010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Smilenov LB, Mikhailov A, Pelham RJ,
Marcantonio EE and Gundersen GG: Focal adhesion motility revealed
in stationary fibroblasts. Science. 286:1172–1174. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Alajez NM, Lenarduzzi M, Ito E, Hui AB,
Shi W, Bruce J, Yue S, Huang SH, Xu W, Waldron J, et al: MiR-218
suppresses nasopharyngeal cancer progression through downregulation
of survivin and the SLIT2-ROBO1 pathway. Cancer Res. 71:2381–2391.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chiyomaru T, Enokida H, Tatarano S,
Kawahara K, Uchida Y, Nishiyama K, Fujimura L, Kikkawa N, Seki N
and Nakagawa M: miR-145 and miR-133a function as tumour suppressors
and directly regulate FSCN1 expression in bladder cancer. Br J
Cancer. 102:883–891. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Song L, Huang Q, Chen K, Liu L, Lin C, Dai
T, Yu C, Wu Z and Li J: miR-218 inhibits the invasive ability of
glioma cells by direct downregulation of IKK-β. Biochem Biophys Res
Commun. 402:135–140. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu DW, Cheng YW, Wang J, Chen CY and Lee
H: Paxillin predicts survival and relapse in non-small cell lung
cancer by microRNA-218 targeting. Cancer Res. 70:10392–10401. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gao C, Zhang Z, Liu W, Xiao S, Gu W and Lu
H: Reduced microRNA-218 expression is associated with high nuclear
factor kappa B activation in gastric cancer. Cancer. 116:41–49.
2010.
|
|
18
|
Mani M, Carrasco DE, Zhang Y, Takada K,
Gatt ME, Dutta-Simmons J, Ikeda H, Diaz-Griffero F, Pena-Cruz V,
Bertagnolli M, et al: BCL9 promotes tumor progression by conferring
enhanced proliferative, metastatic and angiogenic properties to
cancer cells. Cancer Res. 69:7577–7586. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Takada K, Zhu D, Bird GH, Sukhdeo K, Zhao
JJ, Mani M, Lemieux M, Carrasco DE, Ryan J, Horst D, et al:
Targeted disruption of the BCL9/β-catenin complex inhibits
oncogenic Wnt signaling. Sci Transl Med. 4:148ra1172012. View Article : Google Scholar
|
|
20
|
Nantel F, Monaco L, Foulkes NS, Masquilier
D, LeMeur M, Henriksén K, Dierich A, Parvinen M and Sassone-Corsi
P: Spermiogenesis deficiency and germ-cell apoptosis in CREM-mutant
mice. Nature. 380:159–162. 1996. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhao JJ, Lin J, Zhu D, Wang X, Brooks D,
Chen M, Chu ZB, Takada K, Ciccarelli B, Admin S, et al: miR-30-5p
functions as a tumor suppressor and novel therapeutic tool by
targeting the oncogenic Wnt/β-catenin/BCL9 pathway. Cancer Res.
74:1801–1813. 2014. View Article : Google Scholar : PubMed/NCBI
|
